BOSTON--(BUSINESS WIRE)--OM1, the leader in real-world evidence generation and insights for life sciences, proudly announces the appointment of Catherine Richards, PhD, MPH, as its first President. Richards will oversee the Product, Engineering, Clinical Informatics, Client Services, Data Science, and Research teams. Her leadership will be pivotal in advancing OM1’s strategy, innovation, and collaboration to improve patient outcomes.
"We’ve made tremendous strides as an organization over the past decade. But the more we accomplish, even more must be done to improve patient outcomes," said Dr. Richard Gliklich, Founder and CEO of OM1. "Marking the next stage in our growth, Catherine is the perfect person to lead our teams as we aim to match the pace of our ever-evolving industry and continue advancing our technology. Her experience and passion to continuously drive change through innovation and data-driven decisions to improve healthcare outcomes are aligned with our mission, and I’m confident her leadership will help us set new industry standards.”
Richards joins OM1 from ConcertAI, where she served as General Manager of the Real World Evidence Business Unit, leading a global team of 500+ employees and driving significant growth and innovation in oncology-focused data solutions and outcomes services. Prior to ConcertAI, she was the Senior Vice President of Analytics & Scientific Engagement at Panalgo, where she played a crucial role in the rapid rise of their real-world evidence platform. Earlier in her career, Richards held leadership roles at Aetion, Inc., Fred Hutchinson Cancer Research Center, and Columbia University, where she made significant contributions to advance outcomes research and the uses of real-world data.
Richards holds a master's and PhD in Epidemiology from Columbia University and a BA cum laude in the History and Sociology of Science from the University of Pennsylvania.
“Healthcare and life sciences is at a true inflection point as we uncover ways to integrate advanced technology to improve patient care. It’s an honor to join OM1 and work alongside such a passionate and skillful team dedicated to improving the quality and longevity of people’s lives,” said Richards. “Together, we have an opportunity to push the boundaries of what’s possible in improving patient care with real-world data and evidence."
To learn more about OM1’s real-world data, evidence generation, and AI & predictive medicine solutions, please email info@om1.com.
About OM1
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWD/RWE. They have written the handbook on building clinical registries and developing the outcomes measure framework. OM1’s unprecedented innovation takes RWE from bench to practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research.
